Annapurna Therapeutics is a gene therapy company focused on discovering and developing new therapeutic products for people living with severe diseases. 

Annapurna’s product pipeline includes programs for: alpha-1 antitrypsin (A1AT) deficiency, hereditary angioedema (HAE), the cardiomyopathy associated with Friedreich’s ataxia and severe allergy. There is a significant unmet medical need for each of these diseases, and we believe that our adeno-associated virus (AAV)-based gene therapy products, by providing a one-time treatment, have the potential to make a meaningful difference in improving patients’ lives.

We are passionate in our quest to serve and bring hope to patients and their families living with severe diseases, and value our relationship with patient communities and the organizations that serve them. Through our commitment to pharmaceutical research and development in an innovative, focused and ethical manner, we are dedicated to transform treatment paradigm in a range of severe diseases where treatment options are limited.